title: Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients.
authors.forename: Marc
authors.initials: M
authors.lastname: Salzberg
authors.forename: Markus
authors.initials: M
authors.lastname: Borner
authors.forename: Jean-Alexandre
authors.initials: JA
authors.lastname: Bauer
authors.forename: Rudolf
authors.initials: R
authors.lastname: Morant
authors.forename: Daniel
authors.initials: D
authors.lastname: Rauch
authors.forename: Christoph
authors.initials: C
authors.lastname: Rochlitz
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000235:genetics; D004334:Drug Administration Schedule; D006801:Humans; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab